{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:57:58Z","timestamp":1775613478198,"version":"3.50.1"},"reference-count":45,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T00:00:00Z","timestamp":1332374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Granulomatous slack skin (GSS) is a rare cutaneous disorder characterized by the evolution of circumscribed erythematous loose skin masses, especially in the body folds, and histologically by a loss of elastic fibers and granulomatous T\u2010cell infiltrates. This disease is often associated with preceding or successive lymphoproliferative malignancies, especially Mycosis Fungoides (MF) and Hodgkin\u2019s Disease (HD). Whether Granulomatous Slack Skin Disease is a benign disorder, an unusual host reaction or a precursor of malignant lymphoma or an indolent Cutaneous T\u2010cell Lymphoma (CTCL) in itself, is still a controversy. This article reviews its literature on the etiology, clinical findings, and treatment of Granulomatous Slack Skin Disease. It also concentrates on its association with Hodgkin\u2019s disease and its comparison with Mycosis Fungoides and Sezary Syndrome.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04513.x","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T06:40:03Z","timestamp":1332484803000},"page":"1472-1478","source":"Crossref","is-referenced-by-count":37,"title":["Granulomatous slack skin disease: a review, in comparison with mycosis fungoides"],"prefix":"10.1111","volume":"26","author":[{"given":"A.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Safaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,22]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"New Zealand Dermatological Society.Granulomatous slack skin disease.2006. URLhttp:\/\/www.dermnetnz.com(last accessed: 29 June 2011)."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017929"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07526.x"},{"key":"e_1_2_6_6_2","first-page":"178","volume-title":"Pathology and genetics of skin tumours","author":"Kemph W","year":"2006"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155501750208182"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.46"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31803071a4"},{"key":"e_1_2_6_10_2","first-page":"435","article-title":"Skin granulomatous slack","volume":"17","author":"Teixeira M","year":"2007","journal-title":"Eur Dermatol J"},{"key":"e_1_2_6_11_2","first-page":"189","article-title":"Granulomatous slack skin: a case of unusual variant of mycosis fungoides","volume":"113","author":"Chen M","year":"2000","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320100281"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316742"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70597-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80226-5"},{"key":"e_1_2_6_16_2","first-page":"415","volume-title":"Treatment of Skin Disease Comprehensive Therapeutic Strategies","author":"Jeremy RM","year":"2005"},{"key":"e_1_2_6_17_2","first-page":"349","volume-title":"Cancer of Skin","author":"Hymes KB","year":"2005"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin\u201012 therapy of lymphoma cutaneous T\u2010cell regression induces lesion, responses cytotoxic T\u2010cell","volume":"94","author":"Rook AH","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1622"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910580123"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90119-X"},{"key":"e_1_2_6_22_2","first-page":"629","article-title":"Photopheresis therapy of cutaneous T\u2010cell lymphoma: the Yale\u2010New Haven Hospital experience","volume":"62","author":"Heald PW","year":"1989","journal-title":"Yale J Biol Med"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80279-4"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80062-4"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02380.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70307-N"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660320030004"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/0001555566361363","article-title":"Pyrogallol in tumour stage of mycosis fungoides: a case report","volume":"66","author":"Van de Kerkhof PC","year":"1986","journal-title":"Acta Derm Venerol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and sezary syndrome: a comparision of isotretinoin and etretinate \u2013 a study from scandinavian mycosis fungoides group","volume":"67","author":"Molin L","year":"1987","journal-title":"Acta Derm Venerol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06360.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.11.1343"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb14917.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.9.1112980"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025999"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"e_1_2_6_37_2","first-page":"27","article-title":"Phase II multi\u2010institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T\u2010cell lymphoma","volume":"10","author":"Piekarz RL","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8552","article-title":"Long\u2010term treatment of CTCL with the oral PNP inhibitor, Forodesine","volume":"27","author":"Duvic M","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_39_2","first-page":"S2","article-title":"Pralatrexate efficacy and tolerability in patients with relapsed or refractory cutaneous T\u2010cell lymphoma (CTCL)","volume":"95","author":"Horwitz SM","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.582202"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1190"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000070962"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.10.1359"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2455"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903216770"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04513.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04513.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:38:15Z","timestamp":1697359095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04513.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04513.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04513.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}